Myasthenia gravis (MG) is an autoimmune disorder that affects the postsynaptic neuromuscular junction membrane. Acetylcholine receptor (AChR) antibodies are frequently present, and the number of functioning postsynaptic receptors is reduced. Muscle-specific kinase antibodies may be identified in individuals with and without AChR antibodies.1 Ptosis or diplopia due to ocular muscle involvement are frequently the first symptoms of the disease.2 Approximately half of the patients are first seen with purely ocular MG (OMG); of these, 53% develop generalized MG (GMG) within 2 years (> 80% in the first year). Furthermore, a spontaneous remission rate of 30% has been reported in patients with OMG during a 15-year period.3 Both AChR and muscle-specific kinase antibodies may be present in OMG.4
Gilbert ME, De Sousa EA, Savino PJ. Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy. Arch Neurol. 2007;64(12):1790–1792. doi:10.1001/archneur.64.12.1790
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.